Nice to see, this was originally posted elswhere by

New Post Public Reply Private Reply Replies (0) Message Board
AlanC
Nice to see, this was originally posted elswhere by 4kids:

Hong Kong Tribunal Rules Against U.S. Short-Seller Andrew Left

Market Misconduct Tribunal finds Left was ‘reckless’ or ‘negligent’ in spreading information
WALL STREET JOURNAL
By JULIE STEINBERG
Updated Aug. 26, 2016 7:02 a.m. ET

HONG KONG—A Hong Kong tribunal found U.S. short-seller Andrew Left, best known for his critique of drug company Valeant Pharmaceuticals International Inc., was “reckless” or “negligent” for spreading false and misleading information about a Chinese property developer.

Hong Kong’s Market Misconduct Tribunal ruled in favor of the city’s securities regulator and against Mr. Left, a Los Angeles-based short seller who published a scathing report on Hong Kong-listed Evergrande Real Estate Group Ltd.—now called China Evergrande Group—in 2012.

The tribunal in its decision Friday said Mr. Left’s allegations of “insolvency” and “fraudulent accounting” at Evergrande were false, and that he should have checked with an expert and the company before publishing them. Mr. Left could face penalties, to be determined later, that include giving up his profits on the trade and a ban from trading for a period in Hong Kong.

The civil case, which the tribunal heard earlier this year, spotlights regulators’ concerns over analysts and traders who point to alleged problems at companies and bet that their share prices will fall. Some say short sellers benefit the market by digging up damaging information that might not otherwise surface. Others say they publish misleading comments to profit from driving down stock prices.

The debate over what constitutes allowable commentary has taken on particular urgency in Hong Kong in recent months. A different tribunal in March said ratings giant Moody’s Investors Service must pay 11 million Hong Kong dollars (US$1.4 million) because of errors and “misleading and unfair” language in a July 2011 report that highlighted “red flags” at certain Chinese companies. Moody’s is appealing the decision.

Shareholder activists say they fear such cases, which indicate closer scrutiny by regulators, could have a chilling effect on free speech in Hong Kong’s markets.

Mr. Left said in a phone interview he is considering an appeal. Hong Kong’s securities regulator in a press release thanked the U.S. Securities and Exchange Commission for its help with the case. The legal action is the first brought by the regulator against a short seller.

Mr. Left’s Citron Research publishes reports often peppered with profanity and taunts aimed at corporate executives. He frequently appears on U.S. business television channels to pan stocks, including a recent broadside against Facebook Inc. He says investors don’t fully appreciate the threat that the social-networking site faces from upstarts like Snapchat, and that Facebook isn’t worth its $353 billion market capitalization.

The 45-year-old Mr. Left lives in a mansion overlooking Los Angeles, across the street from Slash, the former lead guitarist of rock band Guns N’ Roses. Mr. Left invests only his own money and said he has made profits every year since he started short selling 15 years ago.

He gained prominence for his criticisms of Valeant’s accounting in October 2015, when he suggested that Valeant had used its relationship with a mail-order pharmacy to commit fraud. Valeant denied Mr. Left’s allegations, but the company has restated past earnings because of its relationship with the pharmacy. The Wall Street Journal has reported that Valeant is under criminal investigation.

Mr. Left’s criticisms contributed to a sharp decline in Valeant’s stock, which at one point had declined more than 90% from its high. Mr. Left had a short position in Valeant as recently as July, but he said Thursday that he doesn’t currently hold any position. A Valeant spokesman declined to comment.

In the Evergrande case, Mr. Left sold short 4.1 million shares of the company before publishing a report on his website on June 21, 2012, claiming the property developer was “insolvent” and had used “at least six accounting shenanigans to hide it.”

After publishing the report, Mr. Left bought back the shares for a total realized profit of HK$1.7 million. On the day the report was published, Evergrande’s share price fell as much as 20% before closing down 11.4% at 3.97 Hong Kong dollars (around 51 U.S. cents).

A spokesman on Friday couldn’t be reached, but Evergrande has denied the allegations in the past. Moody’s in January of this year downgraded the company’s debt deeper into junk territory amid concerns about the developer’s debt-funded growth strategy. Profit attributable to shareholders fell 17% in 2015 from a year earlier, while revenues were up 20%.

In its decision released Friday, the tribunal said Mr. Left’s allegations of accounting tricks “displayed a significant ignorance of the accountancy standards” Evergrande had to follow.

The tribunal said that when Mr. Left published his report on Evergrande, he “consciously disregarded the real risk” that it was “false and/or misleading as to material facts.”

Mr. Left didn’t consult an accounting expert regarding the allegations he made in the report, and didn’t contact the company before publishing, the tribunal said, thereby shirking his “obligation.” Mr. Left also “must have appreciated” his report’s impact on other investors, the tribunal wrote.

The tribunal is setting too high a bar for publishing commentary, Mr. Left said.

“What company would ever say ‘you’re right’?” when confronted with allegations of fraud, he said.

Mr. Left said the ruling was biased against short sellers. Bullish analysts haven’t been similarly charged for writing positive reports on stocks that later tanked, he said.

“If you don’t like my commentary, it’s reckless,” he said. “But if you do, it’s not.”

Lawyers for Hong Kong’s securities regulator and Mr. Left have three weeks to suggest appropriate penalties to the tribunal.

—Michael Rapoport contributed to this article.

Write to Julie Steinberg at julie.steinberg@wsj.com

http://www.wsj.com/articles/hong-kong-tribuna...1472185068

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

La Compagnie Unveils NYC-Düsseldorf Flight Plans

Updated Category News Views 2

A new chapter is unfolding in the skies over the Atlantic. La Compagnie is gearing up to connect New York to Düsseldorf with a direct, all-business-class flight starting in Spring 2027. This move is ambitious, tapping into the bustling economic energy present across the North Rhine-Westphalia region—an economic powerhouse littered with U.S.-affiliated businesses. A...

Continue Reading
Advenica: Rising Star in Secure File Transfer Market

Updated Category News Views 0

Advenica's Ascent in Secure File Transfer The cybersecurity world never sleeps, and with the rapid pace of digital threats, it's no surprise that secure file transfer solutions are becoming hotter commodities than coffee pots on Wall Street. Advenica, a name that might not ring a bell for everyone, has emerged as an 'Emerging Leader' in MarketsandMarkets' latest...

Continue Reading
Beazer Homes Sale Scrutinized for Shareholder Impact

Updated Category News Views 1

Spotlight on Beazer Homes' Proposed Sale Here's a real head-scratcher for folks in the stock trenches: Beazer Homes USA, Inc. (NYSE: BZH) finds itself under the microscope with Halper Sadeh LLC stirring the pot. You can't make this up—just another day in the world of investor rights and looming litigation. Questions Arise Over Shareholder Gains Halper Sadeh LLC, that...

Continue Reading
vivo and UNESCO Unite Youth for Nature Stories

Updated Category News Views 3

Young Creators Explore Nature Through a New Lens Pontremoli, Italy just became the backdrop for an extraordinary gathering of young visionaries. From August 31 to September 5, UNESCO’s Man and the Biosphere (MAB) Programme and vivo wrapped their 2026 Capture the Future initiative in the lush landscapes of the Appennino Tosco Emiliano Biosphere Reserve. It’s one thing...

Continue Reading
Navimow Powers TOP 14 with Tech: A Winning Play

Updated Category News Views 4

A Technological Leap for French Rugby Innovation and precision in partnerships—those words don't usually pop up together when chatting about a rugby league. But here we are, discussing the TOP 14, the elite French rugby championship, pairing up with Segway Navimow. This brand, under the umbrella of Ninebot Limited (689009.SH), is stepping into the world of sports for...

Continue Reading
Reliable Safety & Flow: A New Era in Infrastructure

Updated Category News Views 1

Seismic Merger: Reliable Sprinkler and ASC Join Forces When two companies with roots stretching back to the 1800s decide to merge, it's not just a business move—it's a bold statement. Reliable Automatic Sprinkler and ASC Engineered Solutions, with over 175 years of combined innovation, have officially become Reliable Safety & Flow Corporation. This ain't just a...

Continue Reading
BYD's Chip Mastery Amid China's Auto Supply Tensions

Updated Category News Views 7

Chips, the New Battleground in Automotive Innovation Here we are, folks, knee-deep in a tech-driven car revolution where semiconductors aren't just the icing on the cake—they're the cake itself. As vehicles morph into veritable computers on wheels, reliance on chips is hitting a fever pitch. FYI, it's not just about making cars go; we're talking power management,...

Continue Reading
KuCoin's KCUSD Tackles Stablecoin Idle Capital Problem

Updated Category News Views 1

KuCoin's Bold Move with KCUSD Folks, the cat's outta the bag with KuCoin's latest maneuver—introducing KCUSD. At first glance, it seems like they're just introducing another fancy stablecoin product, but peel the onion and there's more to it. We're talking about shaking up how stablecoins sit tight doing nada in the crypto world. KCUSD is out to make those idle balances...

Continue Reading
Wooree Group Pushes for Rigorous Liposome Standards

Updated Category News Views 0

Rallying for Rigorous Scientific Validation Ever find yourself pondering how many so-called 'innovative' health products really deliver what they promise? Let me tell ya, Wooree Group’s CEO, Ji-yong Yoon, ain’t buying into flimsy claims. At the Vitafoods Asia 2026 event in Bangkok, Yoon sent a clear message: Without scientific validation, calling a product 'liposomal'...

Continue Reading
Snack Bars Market to Hit $32.66B by 2031: Growth and Challenges

Updated Category News Views 1

Snack Bars Navigate a Transforming Market There's a headwind in the snack bars market as it looks to lift off from $21.94 billion and land at $32.66 billion by 2031. That's a solid climb at an 8.28% CAGR. What's fueling this leap? A desire for convenient, portable nutrition that's squeezing into every nook of modern life—from the gym to the car, to your kid's lunchbox....

Continue Reading

Top 5 Most Recently Viewed Articles

Yi Shi Celebrates Charity Lunch Win with Marc Benioff at GLIDE

Updated Category News Views 155

Yi Shi's Remarkable Achievement with Marc Benioff Yi Shi, the visionary Founder and CEO of FlashIntel, has recently triumphed in a remarkable charity lunch auction alongside Marc Benioff, the esteemed Chair and CEO of Salesforce. This event is part of the annual GLIDE Power of One Charity Lunch, which aims to generate crucial support for combating social issues like...

Continue Reading
Renaissance Technologies Expands Portfolio with Key Moves in 2024

Updated Category News Views 303

Renaissance Technologies: A Legacy of Success Renaissance Technologies has established itself as a titan in the hedge fund industry. Known for its impressive track record, the firm's Medallion Fund has achieved astonishing annualized returns of 39% from 1998 to 2021. Despite the passing of its legendary founder Jim Simons, the firm continues to make waves in the...

Continue Reading
Paragon 28 Reveals Strong Preliminary Revenue for 2024

Updated Category News Views 255

Paragon 28 Reports Preliminary Revenue Growth for 2024 Paragon 28, Inc. (NYSE: FNA), a prominent player in the medical device industry, has announced its preliminary unaudited revenue figures for the fourth quarter and the entire fiscal year ending in 2024. With its focus solely on the foot and ankle orthopedic market, Paragon 28 continues to demonstrate impressive growth...

Continue Reading
Palvella Therapeutics Embraces Growth with Q3 2025 Results

Updated Category News Views 151

Palvella Therapeutics Celebrates Third Quarter Success Palvella Therapeutics, Inc. (NASDAQ: PVLA) continues to pave the way in rare disease treatment with its QTORIN™-derived product candidates, addressing four serious skin disorders with no FDA-approved therapies available. This is a significant leap forward in providing hope to patients suffering from these...

Continue Reading
Crédit Agricole Assurances' Upcoming Notes Redemption Explained

Updated Category News Views 170

Crédit Agricole Assurances Announces Note Redemption Crédit Agricole Assurances S.A. has made a significant announcement regarding its Undated Subordinated Resettable Notes issued end January 2015. This decision marks an essential step in the company’s ongoing strategy to manage its financial resources effectively. Details of the Redemption The company has confirmed...

Continue Reading